Head-to-head · WeighScore
SnagRx vs Zealthy
The verdict
SnagRx takes it — 57.9/100 to 46.7/100.
SnagRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. SnagRx is a cash-pay GLP-1 telehealth service from Modern Metabolic Medicine, Inc.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | SnagRx | Zealthy |
|---|---|---|
| WeighScore | 57.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #387 | #496 |
| Semaglutide | $299/mo (starting dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $399/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #387 · C
Strengths
- Compounded semaglutide ($99/mo) and tirzepatide ($149/mo) on launch discount, flat-priced at every dose
- Names four partner pharmacies in Terms (RedRock, Health Warehouse, Precision Compounding, Triad Rx)
- Available in all 50 states plus Washington D.C. per Terms
- Telemed visit, prescription and free 1-2 day shipping included; no insurance or membership
- Cancel anytime; full refund if disqualified by the medical provider
Where it loses points
- Headline $99/$149 prices are discounted from $299/$399 standard; a countdown timer pressures signup
- No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only
- Refunds only available before medication is ordered; all sales otherwise final
- Binding JAMS arbitration under Delaware law; class-action waiver
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.